<DOC>
	<DOC>NCT01741831</DOC>
	<brief_summary>The purpose of this study is to assess the safety data of darunavir in a natural clinical practice.</brief_summary>
	<brief_title>A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Prezista</brief_title>
	<detailed_description>This is a non-interventional (a scientific study to make a clear and easy understanding of the cause and effect relationship), prospective (in which the participants are first identified and then followed forward as time passes), consecutive survey for collecting safety and efficacy data of darunavir in treatment of Acquired Immune Deficiency Syndrome (AIDS) in a natural clinical practice.</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>Patients who are prescribed with darunavir for treatment of Acquired Immune Deficiency Syndrome (AIDS) Known hypersensitivity to Prezista Prezista coadministered with medicinal products that are highly dependent on CYP3A for clearance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Acquired Immune Deficiency Syndrome</keyword>
	<keyword>AIDS</keyword>
	<keyword>TMC114</keyword>
	<keyword>Darunavir</keyword>
	<keyword>Prezista</keyword>
</DOC>